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Protein kinase C-y (PKC-y) becomes activated in pancreatic acini in response to cholecystokinin (CCK) and plays a pivotal role in the exocrine
pancreatic secretion. Rottlerin, a polyphenolic compound, has been widely used as a potent and specific PKC-y inhibitor. However, some recent
studies showed that rottlerin was not effective in inhibiting PKCy activity in vitro and that may display unspecific effects. The aims of this work
were to investigate the specificity of rottlerin as an inhibitor of PKC-y activity in intact cells and to elucidate the biochemical causes of its
unspecificity. Preincubation of pancreatic acini with rottlerin (6 AM) inhibited CCK-stimulated translocation, tyrosine phosphorylation (TyrP) and
activation of PKC-y in pancreatic acini in a time-dependent manner. Rottlerin inhibited amylase secretion stimulated by both PKC-dependent
pathways (CCK, bombesin, carbachol, TPA) and also by PKC-independent pathways (secretin, VIP, cAMP analogue). CCK-stimulation of MAPK
activation and p125FAK TyrP which are mediated by PKC-dependent and -independent pathways were also inhibited by rottlerin. Moreover,
rottlerin rapidly depleted ATP content in pancreatic acini in a similar way as the mitochondrial uncouplers CCCP and FCCP. All studied inhibitory
effects of rottlerin in pancreatic acini were mimicked by FCCP (agonists-stimulated amylase secretion, p125FAK TyrP, MAPK activation and PKC-
y TyrP and translocation). Finally, rottlerin as well as FCCP display a potent inhibitory effect on the activation of other PKC isoforms present in
pancreatic acini. Our results suggest that rottlerin effects in pancreatic acini are not due to a specific PKC-y blockade, but likely due to its negative
effect on acini energy resulting in ATP depletion. Therefore, to study the role of PKC-y in cellular processes using rottlerin it is essential to keep in
mind that may deplete ATP levels and inhibit different PKC isoforms. Our results give reasons for a more careful choice of rottlerin for PKC-y
investigation.
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PKCs are a family of phospholipid-dependent serine/
threonine protein kinases that play key regulatory roles in
numerous cellular processes [1–5]. To date the PKC family
includes 11 structurally related isoenzymes, which are classi-
fied into three groups based on their structure and allosteric
requirements as conventional (cPKC: a, hI, hII and g), novel
(nPKC: y, (, D and u) and atypical PKC’s (aPKC: ~ , k/L and A
or PKD) [3,4,6].0167-4889/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2005.10.007
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E-mail address: ljgarcia@unex.es (L.J. Garcı´a-Marı´n).The number of PKC isoforms represents a great challenge to
the understanding of PKC function. Several chemical com-
pounds have been developed to selectively inhibit the PKC
activity and, therefore, to determine the biological roles of PKC
in different tissues. Some of these inhibitors display different
degree of specificity for different PKC isoforms [7,8].
Rottlerin, a polyphenolic compound, was described in 1994
as a specific PKC-y inhibitor [9] and has been widely used to
assess the PKC-y role in numerous processes in different cell
[2,9–15]. Using rottlerin alone or in combination with other
techniques it has been reported that PKC-y regulates ERK1/2
activation by PDGF, ATP and phorbol esters in vascular
smooth muscle cells [12]; controls cell proliferation and cell
cycle in SKBR-3 breast cancer cells [13]; regulates Cl-/OH-ta 1763 (2006) 25 – 38
http://www
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and controls apoptotic and necrotic cell death induced by
hypoxia in heart-derived cells [15]. Moreover, rottlerin has
been used in pancreatic acini to provide evidence that PKC-y is
involved in the regulation of the CCK-stimulated amylase
secretion [11], and in the regulation of apoptotic processes in
human pancreatic carcinoma cell lines [16].
Recent studies reported that rottlerin inhibits the activity of
additional unrelated kinases with similar of higher potency than
PKCy [17] and it was not effective in blocking PKCy activity
in vitro [17,18]. Moreover, rottlerin can have effects on
mitochondrial membrane potential [18–20] that correlates with
a depletion of the cellular ATP concentration and with a
subsequent general inhibition of cellular processes [19].
It is well established that PKC plays a pivotal role in the
mechanism of action of the pancreatic secretagogues such as
acetylcholine (Ach) and cholecystokinin (CCK) [21–23].
Direct activation of PKC with phorbol esters such as 12-O-
tetradecanoylphorbol-13-acetate (TPA) can stimulate the secre-
tion of digestive enzymes, especially when added in combina-
tion with agents that increase the cytosolic Ca2+ concentration
([Ca2+]i) [24,25]. Moreover, PKC is involved in the regulation
of secretagogue-induced tyrosine phosphorylation and/or acti-
vation of different kinases, including p125FAK [26–28], PYK2/
CAKh [28,29], Src family kinases [30] and MAPK [29,31] in
pancreatic acini.
Five different PKC isoforms have been detected in
pancreatic acinar cells, including the conventional PKC,
PKC-a, the novel PKC isoforms, PKC-y, PKC-( and PKC-
u, and the atypical isoform, PKC-~ [32,33]. In these cells
PKC-y undergoes cellular translocation, tyrosine phosphory-
lation (TyrP) and activation in response to phorbol esters
and CCK [34,35]. In these cells PKC-y has also been
involved in the phosphorylation and activation of the focal
adhesion tyrosine kinase PYK2/CAKh by TNF-a [36] or
CCK [37] and in NF-nB activation by TNF-a or long-term
incubation with CCK [37,38]. These recent studies suggest
PKC-y may be an intermediate in the ability of CCK to
cause pancreatitis in pancreatic acinar cells [38]. Further-
more, it has been reported that PKC-y is the isoform
involved in the regulation of pancreatic exocrine secretion
[11].
In the present study, we found that rottlerin decreased
pancreatic acini ATP content in a concentration- and time-
related manner. Moreover, we show that preincubation of
isolated rat pancreatic acini with rottlerin inhibited the exocrine
secretion, MAPK activation and tyrosine phosphorylation
stimulated by both, PKC-dependent and -independent path-
ways. The inhibitory effects described for rottlerin were
mimicked by the mitochondrial uncoupler FCCP. Finally,
rottlerin as well as FCCP display a potent inhibitory effect
on the activation of other PKC isoforms present in pancreatic
acini. These results suggest that if rottlerin is used to study the
role of PKC-y in cellular processes it is essential to keep in
mind that may uncouples mitochondrial respiration and deplete
ATP levels. Our results give reasons for a more careful choice
of rottlerin for PKC-y investigation.2. Materials and methods
2.1. Materials
Male Wistar rats (150–200 g) were obtained from the Small Animals
Section, Veterinary Resources Branch, NIH, Bethesda, MD or from the Animal
Farm, Faculty of Veterinary, UEX, Spain. Purified collagenase (type CLSPA)
from Worthington Biochemicals, Freehold, NJ. COOH-terminal octapeptide of
cholecystokinin (CCK-8) was obtained from Peninsula Laboratories, Belmont,
CA. Anti-PKC-y mAb, anti-p125FAK mAb and anti-Phosphotyrosine (PY20)
mAb were from BD-Transduction Laboratories, Lexington, KY. Anti-PKC-y
Polyclonal Ab and Goat anti-rabbit IgG from Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA. Anti-Phospho-p44/42 MAP Kinase (Thr202/Tyr204), Phos-
pho-PAN PKC, Phospho-PKCa/hII (Thr638/641), Phospho-PKCy (Ser643),
Phospho-PKCu (Thr538), Phospho-PKD/PKCA (Ser916) and Phospho-PKC~/k
(Thr410/403), all polyclonal Ab, were from Cell Signaling Technology, Inc.,
Beverly, MA. Anti-phosphotyrosine mAb (4G10) and recombinant protein A-
agarose were from Upstate Biotechnology, Inc., Lake Placid, NY. Rottlerin,
histone H1, sodium orthovanadate (Na3VO4) and ATPAssay Kit were obtained
from Calbiochem, La Jolla, CA. Carbonyl cyanide 4-(trifluoromethoxy)phe-
nylhydrazone (FCCP), Carbonyl cyanide 3-chlorophenylhydrazone (CCCP),
poly-l-lysine, soybean trypsin inhibitor (SBTI), dimethylsulfoxide (DMSO),
Triton X-100, 12-O-tetradecanoylphorbol 13-acetate (TPA), phenylmethane-
sulfonyl fluoride (PMSF), deoxycholic acid, ethylenediaminetetraacetic acid
(EDTA), ethylene glycol-bis(2-aminoethylether)-N,N,N ,N-tetraacetic acid
(EGTA), sodium pyrophosphate, sodium fluoride (NaF), h-glycerophosphate
and dithiothreitol (DTT) from Sigma, St. Louis, MO. Phosphate-buffered saline
(PBS), pH 7.4, from Biofluids, Rockville, MD. Basal medium Eagle (BME)
amino acids and BME vitamin solution from Gibco Laboratories, Grand Island,
NY. Aprotinin, pepstatin, leupeptin, 4-[2-hydroxyethyl]-1-piperazone ethane-
sulfonic acid (HEPES) and 3-[N-morpholino]-propanesulfonic acid (MOPS)
from Boehringer Mannheim Biochemicals, Indianapolis, IN. 4-(2-aminoethyl)-
benzenesulfonyl fluoride hydrochloride (AEBSF) and bovine serum albumin
(BSA) fraction V from ICN Biomedicals Inc., Aurora, OH. Goat anti-mouse
IgG-horseradish peroxidase conjugate, recombinant protein G-agarose and
enhanced chemiluminescence detection reagents from Pierce, Rockford, IL.
Sodium dodecyl sulfate (SDS), 2-mercaptoethanol, protein assay dye reagent,
Tris/Glycine/SDS buffer (10 times concentrated) and Tris/Glycine buffer (10
times concentrated) from Bio-Rad, Hercules, CA. LIVE/DEAD Viability/
Cytotoxicity Kit was from Molecular Probes, Eugene, OR. Nonidet P-40 and
[g32P]ATP from Amersham, Arlington Heights, IL and nitrocellulose mem-
brane from Schleicher&Schuell, Keene, NH.
2.2. Methods
2.2.1. Tissue preparation
Dispersed rat pancreatic acini were obtained by collagenase digestion [39].
Unless otherwise stated, the standard incubation solution contained (mM):
HEPES (25.5) [pH 7.4]; NaCl (98); KCl (6); NaH2PO4 (2.5); sodium pyruvate
(5); sodium fumarate (5); sodium glutamate (5); glucose (11.5); CaCl2 (0.5);
MgCl2 (1); glutamine (2); albumin 1% (w/v); trypsin inhibitor 1% (w/v);
vitamin mixture, 1% (v/v) and amino acid mixture, 1% (w/v). The incubation
solution was equilibrated with 100% O2 and all incubations were performed
with 100% O2 as the gas phase.
2.2.2. Cellular viability
The viability of pancreatic acinar cells was determined using the LIVE/
DEAD Viability/Cytotoxicity Kit for animal cells following the directions
provided by the manufacturer (Molecular Probes, Eugene, OR). Briefly, cells
were incubated with rottlerin for the time and concentrations indicated, washed
with PBS (37 -C) and placed in the surface of a 22-mm square coverslip,
pretreated overnight with poly-l-lysine and allowed to dry. Cells were then
covered with 100–150 Al LIVE/DEAD assay reagents (1 AM ethidium
homodimer-1 and 1 AM calcein-AM) and incubated for 30 min at room
temperature. After that, excess of reagent was removed by washing with PBS
and samples were examined with an inverted fluorescence microscope Nikon
Diaphot 200 (Nikon, Tokyo, Japan). Two images were taken under the optimal
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homodimer-1 (on DNA)=528/617 nm] from different regions of the slide
randomly chosen. Both images were merged using the software Confocal
Assistant, version 4.02, (Bio-Rad, Hercules, CA) and the percentage of dead
and live cells was objectively quantified on the collected images using the
software Scion Image for Windows, version 4.02, distributed by Scion Corp.,
Frederick, MD.
2.2.3. Amylase secretion
Secretagogue-induced amylase release in pancreatic acini was estimated
after 30 min incubation in standard medium at 37 -C using the Phadebas
amylase test as described previously [39,40]. Amylase secretion was expressed
as percentage of amylase released into the extracellular medium during the
incubation of the total cellular amylase.
2.2.4. Cellular adenosine-5V-triphosphate quantification
Total adenosine-5V-triphosphate (ATP) contained in pancreatic acinar cells
was estimated using the Calbiochem ATP Assay Kit following the directions
provided by the manufacturer. All reactions were performed by triplicate in a
final volume of 500 Al. Briefly, pancreatic acini were incubated at 37 -C with
different inhibitors for the time and concentrations specified. After preincuba-
tion, cells were washed with PBS at 37 -C and 200 Al of the cell suspension
were placed into a cuvette and mixed thoroughly with 200 Al of releasing
reagent. The reaction was initiated by adding 100 Al of the luciferase solution
and light emission was measured immediately after that using a Monolight
luminometer, Model 2010 (Analytical Luminescence Laboratory, Sparks, MD).
To determine the background emission all components of the reaction were
added, except the cell suspension (i.e., 200 Al of PBS, 200 Al of the releasing
solution and 100 Al of the luciferase solution). ATP concentration was
estimated using standard curves performed for every single experiment and
values were finally expressed for all time points as percentage of the ATP
contained in pretreated cells referred to the amount of ATP found in control
cells at time zero (=100%). Variation of the ATP quantity in control cells along
all the incubation points was lower than 5%.
2.2.5. Immunoprecipitation
Immunoprecipitation of PKC-y or tyrosine-phosphorylated proteins was
performed as described previously [26,41]. Briefly, dispersed acini from one rat
were preincubated for up to 3 h at 37 -C in standard incubation solution without
or with different inhibitors, at concentrations and times specified. After
preincubation cellular aliquots of 1 ml were incubated at 37 -C with CCK-8 (10
nM; 2.5 min) or TPA (1 AM; 5 min) and washed with ice-cold PBS. Lysates
were obtained from these aliquots by sonication in lysis buffer [50 mM Tris/
HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% (w/v)
NaN3, 1 mM EGTA, 0.4 mM EDTA, 2.5 Ag/ml aprotinin, 2.5 Ag/ml pepstatin,
2.5 Ag/ml leupeptin, 1 mM PMSF and 0.2 mM Na3VO4]. Protein concentration
was estimated and lysates (1 ml; 500 Ag) were incubated with 4 Ag of anti-
phosphotyrosine mAb (PY20) or 4 Ag of anti-PKC-y polyclonal Ab and 25 Al of
protein A-agarose overnight at 4 -C. Immunoprecipitates were finally washed
three times with PBS and further analyzed by SDS-polyacrylamide gel
electrophoresis (PAGE) and Western blotting.
2.2.6. Subcellular fractionation
Acinar cell were fractionated into two major subcellular fractions, i.e.,
cytosolic and membrane fractions, according to the procedures published
previously [35]. Briefly, acinar cells were precipitated by centrifugation,
washed at 4 -C with phosphate-buffered saline (PBS) containing 0.2 mM
Na3VO4, centrifuged, resuspended in 1 ml of lysis buffer without detergents
and homogenized using a Polytron homogenizer (Brinkmann Instruments,
Westburg, NY) for 30 s at power level 6 at 4 -C. Homogenates were first
centrifuged at low speed (500 g) for 10 min at 4 -C to precipitate nuclei, debris
and fat. The supernatant was centrifuged for 30 min at 60000 g at 4 -C to
separate the membrane fraction (pellet) and cytosol fraction (supernatant). After
it isolation, plasma membranes were washed twice with PBS with 0.2 mM
Na3VO4 at 4 -C, resuspended in 150–300 Al of regular lysis buffer (containing
detergents and 150 mM NaCl) and sonicated for 5 s at 4 -C. Membrane lysates
were then centrifuged at 10,000g for 15 min to remove detergent insolublecomponents. After determination of the protein concentration, three volumes of
cytosol or membrane lysates were mixed with 1 volume of loading buffer 4
and equal amount of protein was analyzed by SDS-PAGE followed by Western
blotting.
2.2.7. Western blotting
Western blotting was performed as described previously [26,29,41]. Anti-
phosphotyrosine or anti-PKC-y immunoprecipitates or whole cell lysates (25 Ag
proteins/well) were fractionated by SDS-PAGE using both, 10% polyacrylamide
gels or 4–20% polyacrylamide gradient gels, and proteins were transferred to
nitrocellulose membranes. Membranes were blocked overnight at 4 -C using
TBS-Tween [50 mMTris/HCl pH 8.0, 2 mMCaCl2, 80 mMNaCl and 0.05% (v/
v) Tween 20] with 5% (w/v) non-fat dried milk, and incubated in this solution for
120 min at 25 -C with 0.67 Ag/ml of anti-phosphotyrosine mAb (4G10), or with
1 Ag/ml of anti-PKC-y polyclonal Ab, or with 0.25 Ag/ml anti-p125FAK mAb, or
with 1 Ag/ml anti-phospho-p44/42 MAPK polyclonal Ab. Some antibodies [i.e.,
Phospho-PAN PKC; Phospho-PKCa/hII (Thr638/641); Phospho-PKCy
(Ser643); Phospho-PKCu (Thr538); Phospho-PKD/PKCA (Ser916) and Phos-
pho-PKC~/k (Thr410/403)] were diluted 1/1000 in TBS-Tween with 5% (w/v)
BSA and incubated overnight at 4 -C. After incubation with the primary
antibody, membranes were washed twice and incubated for 45 min at 25 -C with
anti-mouse or anti-rabbit IgG-horseradish peroxidase conjugate. Finally,
membranes were incubated with chemiluminescence detection reagents and
exposed to Biomax AR films (Eastman Kodak Company, Rochester, NY) or
were directly measured in a KODAK Image Station 440CF (Perkin Elmer Life
Sciences, Wellesley, MA). The intensity and molecular weight of bands on films
or membranes was quantified using the software KODAK 1D Image Analysis
(Perkin Elmer Life Sciences, Wellesley, MA).
2.2.8. PKC-d kinase activity assay
Pancreatic acinar cells were preincubated with or without rottlerin,
stimulated with different agents and then lysed without sonication using a lysis
buffer for the kinase assay (LBKA) [137 mM NaCl, 20 mM Tris pH 7.5, 1 mM
EGTA, 1 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Nonidet P-40, 1 mM
Na3VO4, 4.5 mM sodium pyrophosphate, 47.6 mM NaF, 9.26 mM h-
glycerophosphate, 0.5 mM DTT, 2 Ag/ml leupeptin, 2 Ag/ml pepstatin, 2 Ag/
ml aprotinin and 2 Ag/ml AEBSF]. Lysates (1 ml, 900–1000 Ag) were cleared
by centrifugation (15000 g, 15 min) and PKC-ywas immunoprecipitated using 2
Ag of anti-PKC-y mAb for 3 h at 4 -C followed by incubation with 30 Al of
protein G-agarose for 1 h at 4 -C. Kinase assays were performed using the
protein kinase C assay kit from Upstate Biotechnology following the directions
provided by the company with minor modifications. Immune complexes bound
to the protein G-agarose were washed two times with 1 ml of LBKA and two
times with assay dilution buffer (ADB) [20 mM MOPS pH 7.2, 25 mM h-
glycerophosphate, 1 mMNa3VO4, 1 mMDTTand 5 mM EGTA]. Following the
last wash, the pelleted beads were resuspended in 30 Al of ADB containing 5 Ag
of phosphatidylserine and 0.5 Ag of diacylglycerol. The kinase reaction was
initiated with the addition of magnesium/ATP mixture (75 mM MgCl2 and 0.5
mMATP) containing 10 ACi of [g-32P] ATP (3000 Ci/mmol) and the histone H1
(10 Ag) as substrate. The reaction mixtures (final volume 60 Al) were briefly
vortexed and then incubated at 30 -C for 30 min with occasional mixing. After
incubation, the kinase reaction was terminated by adding 15 Al of 4 SDS
sample buffer and boiling the samples for 5 min at 95 -C. Samples were resolved
using 4–20% SDS-PAGE gels. Finally, gels were dried and analyzed in a
phosphoimager (InstantImager, Packard Instruments Co., Meriden, CT).
Background activity was measured using samples where all components of
the reaction were added except PKC substrate.
3. Results
3.1. Effect of rottlerin on PKC-d kinase activity, PKC-d TyrP
and PKC-d translocation in rat pancreatic acini in response to
CCKA receptor activation
Recent studies show that PKC-y is present in pancreatic
acinar cells [32,33] and is tyrosine phosphorylated and
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Rottlerin was described in 1994 by Gschwendt M., et al. as a
specific PKC-y inhibitor (EC50=3–6 AM) [9]. Initially, we
investigated the ability of rottlerin to inhibit kinase activity,
translocation and TyrP of PKC-y in intact pancreatic acini
stimulated by CCK-8. In these cells, 10 nM CCK-8 caused a
marked stimulation (3.2T0.8-fold) of in vitro PKC-y kinase
activity which resulted similar to that obtained with 1 AM TPA
(3.6T0.9-fold) (Fig. 1, top panel, lanes 5 and 3, respectively),
used as a positive control. While pretreatment of pancreatic
acini with 6 AM rottlerin for 2 h did not modify the basal kinase
activity of PKC-y (Fig. 1, top panel, lanes 1 and 2), it howeverFig. 1. Effect of rottlerin on CCK-8 and TPA stimulation of PKC-y kinase activity
(Upper panel) Rat pancreatic acinar cells were pretreated with or without 6 AM rottl
min with TPA (1 AM) and finally lysed. PKC-y was immunoprecipitated with anti-
immunoprecipitates using histone H1 as substrate, as described in Methods. The
duplicate are shown. The location of histone H1 is indicated with the arrow on the l
AM rottlerin for the indicated times, then incubated with no additions, 10 nM CCK-
lysates were immunoprecipitated (IP) with anti-PKC-y polyclonal Ab. Immunopr
nitrocellulose membrane and Western blotting (WB) using anti-phosphotyrosine m
experiment which is representative of three others performed in duplicate. (Bottom pa
and then incubated for 2.5 min with no additions (lanes 1 and 2) or with 10 nM C
described in Methods. Subcellular lysates were fractionated by SDS-PAGE and trans
PKC-y immunoblotting. Shown are total PKC-y (i.e., phosphorylated and non-phosp
experiment are shown and are representative of four independent experiments in dcaused a complete inhibition of the PKC-y activity stimulated
by 1 AM TPA or 10 nM CCK-8 (Fig. 1, top panel, lanes 3, 4, 5
and 6).
As recent studies show that TyrP of PKC-y plays a central
role in the regulation of its kinase activity [35,42], we next
evaluated the effect of rottlerin in the tyrosine phosphorylation
of PKC-y. CCK-8 (10 nM) caused a potent increase in the TyrP
of PKC-y (46T9-fold) (Fig. 1, middle panel, lane 3), which
resulted inhibited by 6 AM rottlerin in a time-dependent
manner; the degree of inhibition was about 29T2%, 64T4%
and 90T3% after 30, 60 and 90 min of preincubation,
respectively (lanes, 6, 9 and 12) and full inhibition of PKC-yand tyrosine phosphorylation, and CCK-8 stimulation of PKC-y translocation.
erin for 120 min, and then incubated for 2.5 min with CCK-8 (10 nM) or for 5
PKC-y mAb from total cell lysates and kinase activity assay was performed on
results from a typical experiment representative of three others performed in
eft. (Middle panel) Rat pancreatic acinar cells were pretreated without or with 6
8 for an additional 2.5 min or with 1 AM TPA for 5 min, and finally lysed. Cell
ecipitates were analyzed by SDS-PAGE followed by transfer of proteins to
Ab (4G10) as described in Methods. The panel shows results from a typical
nel) Pancreatic acini were pretreated with or without 6 AM rottlerin for 120 min,
CK-8 (lanes 3 and 4). Subcellular fractions were obtained by centrifugation as
ferred to nitrocellulose membranes followed by detection of total PKC-y by anti-
horylated) in cytosol (top) and membrane (bottom) fractions. Results of a typical
uplicate.
Fig. 2. Time courses of effect of rottlerin or the mitochondrial uncouplers,
CCCP and FCCP on cellular ATP. Pancreatic acini were preincubated for the
indicated time with no additions (control), 6 AM rottlerin, 10 AM CCCP or 10
AM FCCP. After preincubation, acinar cells were lysed and total cellular ATP
was determined using the Calbiochem ATPAssay Kit, as described in Methods.
Results are expressed as amount of ATP present in the cells preincubated with
the inhibitors, expressed as a percentage of that seen in control cells not
exposed to inhibitors. This result is representative of three others.
J.A. Tapia et al. / Biochimica et Biophysica Acta 1763 (2006) 25–38 29TyrP was obtained after 120 min (lane 15). Similarly, rottlerin
(6 AM) also inhibited in a time-dependent manner the PKC-y
TyrP stimulated by TPA (Fig. 1, middle panel), with a small
effect (7.4T2.3%) after 30 min of preincubation (lane 5),
59T3% of inhibition by 60 min (lane 8) and a complete
inhibitory effect after 90 and 120 min of incubation (lanes 11
and 14, respectively).
Because it has been shown that PKC-y needs to translocate
in order to become TyrP or activated in pancreatic acini [35],
we investigated the effect of rottlerin in the translocation of
PKC-y stimulated by CCK-8. PKC-y is mainly localized in the
cytosol of unstimulated pancreatic acini (Fig. 1, bottom panel,
lane 1). After 2.5 min stimulation with 10 nM CCK-8, PKC-y
rapidly redistributes and increases in the particulate fraction
(Fig. 1, bottom panel, lane 3). Pretreatment for 2 h with 6 AM
rottlerin inhibited by more than 60% the CCK-8-stimulated
PKC-y translocation to particulate fraction (Fig. 1, bottom
panel, compare lanes 3 and 4), without affecting its basal
subcellular localization (Fig. 1, bottom panel, lane 2).
3.2. Effect of rottlerin on intracellular ATP concentration in
pancreatic acini: comparison with the mitochondrial
uncouplers FCCP (carbonyl cyanide
p-trifluoromethoxyphenylhydrazone) and CCCP
(carbonyl cyanide m-chlorophenylhydrazone)
Recent studies report that rottlerin was able to uncouple the
mitochondrial oxidative phosphorylation in some cells [18–
20]. However, it was previously shown in human pancreatic
carcinoma MIA PaCa-2 and PANC-1 cell lines, that longer
rottlerin preincubation failed to alter cellular ATP concentration
[16]. Therefore, we next evaluated the effect of rottlerin on
cellular ATP content in pancreatic acini and compared its
effects with FCCP and CCCP, two protonophores that collapse
the mitochondria inner membrane potential [43] disrupting
mitochondria function.
The intracellular concentration of ATP in untreated pancre-
atic acini remained constant for the period evaluated (3 h) (Fig.
2, control). However, the treatment of pancreatic acini with 6
AM rottlerin was followed by a rapid time-dependent reduction
of the intracellular concentration of ATP (Fig. 2, rottlerin). A
similar effect on the cellular ATP content was obtained by the
treatment of pancreatic acini with 10 AM FCCP and 10 AM
CCCP [43], although the effect of rottlerin was slower than that
achieved with the two classical mitochondrial uncouplers (Fig.
2): While at 30 min, rottlerin reduced the intracellular
concentration of ATP by 37%, FCCP or CCCP decreased the
ATP concentration by 86% and 77%, respectively. While at 60
min, rottlerin inhibited by 69% the ATP concentration, FCCP
or CCCP decreased it by 83% and 94%, respectively. At 120
min rottlerin effect on cellular ATP concentration was similar
to that obtained with CCCP (92% reduction) and slightly
higher than FCCP (98% decrease). Finally, at 180 min rottlerin
reduced by 97% the ATP content (Fig. 2). This effect was
similar to that detected in the cells treated with FCCP (98%)
and slightly higher than that obtained after incubation of
pancreatic acini with CCCP (90%).3.3. Effect of rottlerin on amylase release elicited by different
intracellular pathways in rat pancreatic acini
The most important role of the exocrine pancreas is to
secrete enzymatic proteins involved in the digestive processes
[22,44–46]. Extensive studies show that pancreatic secretago-
gues such as CCK, bombesin and carbachol, an acetylcholine
analogue lead to PKC activation and stimulation of increases in
[Ca2+]i [22,23,44,47,48], which in turn have been shown to
stimulate amylase release on pancreatic acini [24,25,44,49].
Pretreatment for 2 h with 8 AM rottlerin inhibited by 80% the
amylase secretion stimulated by 0.1 nM CCK-8, 1 AM
carbachol or 10 nM bombesin (Table 1). Interestingly,
pretreatment for same time with 10 AM FCCP inhibited the
amylase release stimulated by CCK-8, carbachol or bombesin
with a similar potency than rottlerin (Table 1).
Secretin and VIP intracellular effectors involve cAMP and
protein kinase A (PKA) [44,46] rather than PKC. Secretin- and
VIP-stimulated amylase secretion was also inhibited by 8 AM
rottlerin and 10 AM FCCP, although the later showed slightly
more potency (Table 1). Finally, amylase secretion obtained
bypassing receptors by direct activation of PKCwith TPA (1 AM),
or by using the cAMP cell-permeable analogue, 8Br-cAMP (1
mM), was also inhibited with similar potency by the pretreatment
for 2 h of pancreatic acini with 8 AM rottlerin or 10 AM FCCP
(Table 1). These results demonstrate that rottlerin and FCCP
display a potent inhibitory effect on the amylase release elicited by
Table 1
Effect of rottlerin on agonist-stimulated amylase secretion in rat pancreatic
acinar cells
Amylase secretion (% total)
No addition Rottlerin (8 AM) FCCP (10 AM)
Control 4.26T0.51 2.58T0.09 2.77T0.86
CCK (0.1 nM) 16.75T0.54 4.67T1.48 2.45T0.72
Carbachol (1 AM) 14.69T1.57 4.24T1.25 2.73T0.90
Bombesin (10 nM) 16.60T1.28 4.60T1.86 2.01T0.24
VIP (0.1 AM) 9.85T2.69 3.82T0.26 2.39T0.35
Secretin (0.1 AM) 10.62T1.03 5.03T1.06 3.01T1.05
TPA (1 AM) 13.82T2.56 3.89T0.88 2.63T0.76
8Br cAMP (1 mM) 7.92T1.78 2.99T0.26 3.03T0.85
Pancreatic acinar cells were pretreated for 2 h at 37 -C either in the absence or
presence of 8 AM rottlerin or 10 AM FCCP, and then incubated for a further 30
min with no additions (control) or with the indicated agonists. Amylase
secretion was determined using the Phadebas amylase test as described in
Methods, and expressed as the percentage of acinar cell amylase released into
the medium during the incubation. Results are meansTS.E.M. from four
separate experiments performed in duplicate.
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mechanisms or by direct activation of the PKC-unrelated
intracellular pathways that lead to secretion in rat pancreatic acini.
3.4. Effect of the preincubation with rottlerin on TyrP and
mitogen-activated protein kinase (MAPK) pathway activation
in rat pancreatic acinar cells
In order to study the possible unspecific effect of rottlerin we
evaluated its effects on different signaling pathways that are at
least partially regulated by a PKC-independent mechanism, such
as general TyrP, the TyrP of p125FAK, and the MAPK pathway
stimulated by CCK-8 (Fig. 3) [26–29,50,51]. Incubation of
pancreatic acini with 10 nM CCK-8 (2.5 min) or 1 AM TPA (5
min) greatly increased the tyrosine phosphorylation of a number
of proteins [27], being especially evident in six proteins with
molecular weights comprised between 64 and 200 kDa (Fig. 3,
top panel, see arrows). The pretreatment of pancreatic acini with
6 AM rottlerin caused a time-dependent decrease in the amount
of CCK-8- or TPA- stimulated Tyrp (Fig. 3, top panel). At 120
min, rottlerin inhibited by more than 85% the tyrosine
phosphorylation induced by CCK-8 or TPA of the six mentioned
proteins (Fig. 3, top panel, compare lanes 2–3 with 14–15).
Rottlerin also affected the basal TyrP as progressively decreases
the amount of tyrosine-phosphorylated proteins in unstimulated
cells by more than 70% at 120 min (Fig. 3, top panel, compare
lanes 1, 4, 7, 10 and 13).
One of the proteins most strongly tyrosine-phosphorylated
in pancreatic acinar cells after CCK-8 stimulation is the focal
adhesion tyrosine kinase, p125FAK [26,27] (Fig. 3, top and
middle panel). To further analyze the effect of rottlerin on the
TyrP of p125FAK, we examine the phosphotyrosine-containing
immunoprecipitates by Western blotting with a monoclonal Ab
that specifically recognizes p125FAK (Fig. 3, middle panel)
[26,27]. Incubation of pancreatic acinar cells with 10 nM CCK-
8 (2.5 min) or 1 AM TPA (5 min) strongly stimulated the TyrP
of p125FAK (Fig. 3, middle panel, lanes 2 and 3). Both, the
CCK-8- and TPA-stimulated as well as the basal p125FAK TyrPwere inhibited by 6 AM rottlerin in a time-dependent manner,
with the TyrP decreasing to less than 5% of control after 120
min of preincubation (Fig. 3, middle panel).
Finally, using a specific antibody that recognizes the active
form of the ERK kinases (p44/p42), we studied the effect of
rottlerin on the activation of the MAPK pathway by CCK-8 or
TPA. Once again, rottlerin showed a time-dependent, strong
inhibitory effect on the MAPK activation stimulated by 10 nM
CCK-8 or 1 AM TPA (Fig. 3, bottom panel).
3.5. Effect of the disruption of mitochondria metabolism in
general TyrP, p125FAK TyrP and MAPK activation in rat
pancreatic acinar cells
In order to relate the effect of rottlerin with the disruption of
mitochondria metabolism and the subsequent decline in ATP
concentration within the cell, we performed an additional
experiment using FCCP to investigate whether this agent could
also inhibit the tyrosine phosphorylation of a number of
proteins and the MAPK activation, in a similar fashion to
rottlerin. Preincubation with 10 AM FCCP (Fig. 4) also caused
a time-dependent inhibition of CCK-8- or TPA-stimulated
general TyrP (upper panel), p125FAK TyrP (middle panel) and
ERK1/2 activation (lower panel). However, the inhibition
caused by FCCP in all these processes was faster than that
obtained with rottlerin which correlated with the time-course
decrease of cellular ATP induced by rottlerin and FCCP (Fig.
2). The maximal inhibitory effect on phosphorylation by
preincubation with rottlerin 6 AM was achieved by 120 min
of preincubation (see Fig. 3), and approximately the same level
of inhibition was obtained after 30–60 min of preincubation
with 10 AM FCCP (Fig. 4). Finally, in cells pretreated with
FCCP additional TyrP bands appeared during the incubation
(Fig. 4, upper panel, three bottom arrows on the right). These
additional TyrP bands also appeared in cells treated with
rottlerin for a longer time (data not shown).
3.6. Effect of the disruption of the mitochondria metabolism on
the CCK-8-stimulated translocation and TyrP of PKC-d
We next investigate whether the ATP depletion could explain
the ability of rottlerin to inhibit PKC-y TyrP or its translocation
in intact pancreatic acini. The CCK-8- or TPA-stimulated PKC-y
TyrP was inhibited by the pretreatment for 2 h with 10 AMFCCP
in a time-dependent manner (Fig. 5, top panel). The effect caused
by FCCP was faster than rottlerin (Fig. 1), obtaining full
inhibition of CCK-8- or TPA-stimulated PKC-y TyrP at 60 min
(Fig. 5, top panel, lanes 11–12) which correlate with the time-
dependent curves obtained in the ATP concentration (Fig. 2).
Similarly to the effect achieved with rottlerin (Fig. 1), the
pretreatment for 2 h with 10 AM FCCP did not modify the basal
PKC-y subcellular localization, but inhibited (>85%) CCK-8-
stimulated PKC-y redistribution to the particulate fraction (Fig.
5, bottom panel, lanes 3–4). These results indicate that ATP is
necessary for the CCK-8 stimulated PKC-y TyrP and translo-
cation, which are both essential upstream processes in the PKC-y
activation in intact cells [35,42].
Fig. 3. Time-dependent inhibition of general tyrosine phosphorylation, p125FAK tyrosine phosphorylation and ERK1/2 activation by rottlerin. Rat pancreatic acinar
cells were pretreated with or without 6 AM rottlerin for the indicated times, and then incubated with no additions, with 10 nM CCK-8 or with 1 AM TPA. Pancreatic
acini were lysed, and phosphotyrosine-containing proteins were immunoprecipitated using an anti-phosphotyrosine mAb (top and middle panel) or whole cell lysates
were obtained (bottom panel). Tyrosine-phosphorylated immunoprecipitates were analyzed by SDS-PAGE and Western blotting (WB) with an anti-phosphotyrosine
mAb (4G10) (top panel) or with an anti-p125FAK mAb (middle panel) as described in Methods. In the bottom panel, whole cell lysates were resolved without prior
immunoprecipitation in 4–20% polyacrylamide gradient gels and transferred to nitrocellulose membranes. Western blotting (WB) was performed using an anti-
phosphoERK1/2 (p44/42) polyclonal Ab. Results shown in all panels are from a typical experiment representative of three others.
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expressed in rat pancreatic acinar cells
The activity of PKC is regulated by three distinct
phosphorylations at specific residues which were described
for PKC-hII as the Thr500, Thr641 and Ser660 [3]. Two of
these phosphorylation sites are conserved among classical and
atypical PKC isoforms; however, the atypical PKC isoforms
display a glutamic residue instead a serine or threonine residue
in classical PKC isoforms and, therefore, are not phosphory-
lated at this site [2,10]. Protein kinase D (PKD), also calledPKC-A, is also activated by phosphorylation at specific sites
[52,53] and the catalytic activity of PKD/PKC-A correlates
with its autophosphorylation at the serine 916 [52].
Using antibodies that specifically recognize PKC-a or PKC-~
isoforms only when they are phosphorylated at the Thr638 or
Thr410, respectively, we were unable to find CCK-8-stimulated
PKC-a or PKC-~ phosphorylation at these sites (data not shown).
These results are in agreement with previously published studies
where CCK-8 failed to activate PKC-a [32,38] or PKC-~ [38].
However, the stimulation of pancreatic acini with 10 nM CCK-
8 for 2.5 or with 1 AM TPA for 5 min greatly increased the
Fig. 4. Time-dependent inhibition of general tyrosine phosphorylation, p125FAK tyrosine phosphorylation and MAPK activation by the mitochondrial uncoupler,
FCCP. Rat pancreatic acinar cells were pretreated with or without 10 AM FCCP for the indicated times, followed by incubation with 10 nM CCK-8, with 1 AM TPA
or with no additions. Pancreatic acini were lysed and immunoprecipitates or whole cell lysates were obtained, and subsequent WB were performed as described in
Fig. 7 legend, except 4–20% polyacrylamide gradient gels were used. Results shown in panels are from a typical experiment representative of three others.
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PKCA at Ser916 (Fig. 6, top panel, lanes 1–3). Similar results
were obtained using a phospho-PKC antibody that specifically
detects PKC-a, hI, hII, y, ( and D isoforms only when they are
phosphorylated at the C-terminal residue homologous to Ser660
of PKC-hII (Fig. 6, top panel, PhosphoPAN-PKC, lanes 2–3).
To assess the effect of rottlerin on activation of the other
PKCs in pancreatic acini we pretreated cells with this inhibitor
(6 AM, 2 h) and determined the phosphorylation state of the
above mentioned specific PKC residues. For comparison
purposes we also investigated the effect of the preincubation
for 2 h with 10 AM FCCP. Both, rottlerin and FCCP inhibited
with similar potency the CCK-8- and TPA-stimulated increases
in PKC-y, PKC-u and PKD/PKC-A phosphorylation at thespecific residues (Ser643, Thr538 and Ser916, respectively)
(Fig. 6, lanes 4–9). Such inhibitory effect was also seen using a
Pan-PKC phosphospecific antibody (Fig. 6, top panel). These
results further demonstrate that the effect of rottlerin on PKC
activity cannot be uniquely attributed to the inhibition of the y
PKC isoform and also that the inhibitory effect of rottlerin on
PKC-y activity could be explained by its action on the
mitochondria metabolism in rat pancreatic acini.
3.8. Effect of rottlerin on the viability of rat pancreatic acinar
cells
Finally, we investigated whether the ATP depletion induced
by rottlerin could be affecting the viability of isolated
Fig. 5. Effect of FCCP on CCK-8 and TPA stimulation of PKC-y tyrosine phosphorylation, and CCK-8 stimulation of PKC-y translocation. (Top panel) Rat
pancreatic acinar cells were pretreated with or without 10 AM FCCP for the indicated times, then incubated with no additions, 10 nM CCK-8 for an additional 2.5
min or with 1 AM TPA for 5 min, and finally lysed. Cell lysates were obtained as described in Methods and the Fig. 1 legend. The panel shows results from a typical
experiment which is representative of three others performed in duplicate. (Bottom panel) Pancreatic acini were pretreated with or without 10 AM FCCP for 120 min,
and then incubated for 2.5 min with no additions (lanes 1 and 2), or with 10 nM CCK-8 (lanes 3 and 4). Subcellular fractions were obtained as described in Methods
and the Fig. 1 legend. Total PKC-y was determined by anti-PKC-y immunoblotting. Results shown are representative of three other independent experiments in
duplicate.
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Dead_ (Molecular Probes, Eugene, OR). By using this
technique, live cells appear typically with green fluorescence
and the dead cells with red fluorescence (Fig. 7). The
percentage of viable pancreatic acinar cells used as controlFig. 6. Effect of rottlerin and FCCP on site-specific phosphorylation of different PK
(lanes 1–3), with rottlerin (6 AM) (lanes 7–9) or with FCCP (10 AM) (lanes 4–6)
indicated. Whole cell lysates were obtained and analyzed by immunoblotting withou
isoforms (individually or globally) when are phosphorylated at the indicated specific(92T0.7%) (excipient-treated), was similar to that obtained
after the preincubation of pancreatic acinar cells with 20 AM
rottlerin for 3 h (93T0.9%), as was obtained in nine
independent experiments (Table 2 and Fig. 7). Moreover, both
cellular populations (treated with excipient or rottlerin)C isoforms. Pancreatic acinar cells were preincubated for 2 h with no additions
and then incubated with no additions, with CCK-8 (10 nM) or TPA (1 AM) as
t prior immunoprecipitation with antibodies which specifically recognizes PKC
sites. Results shown are representative of three other independent experiments.
Fig. 7. Effect of rottlerin on the viability of rat pancreatic acinar cells. Rat pancreatic acini were incubated without (left panel) or with 20 AM rottlerin (right panel) for
3 h and then attached to a cover slide pretreated with poly-l-lysine. Subsequently, the cells were loaded for 30 min at room temperature with 1 AM ethidium
homodimer-1 and 1 AM calcein AM (LIVE/DEAD kit, Molecular Probes). After loading, the cells were washed and the cover slides were placed on the stage of an
inverted fluorescence microscope, as described in Methods. Images were taken at 494 nm of excitation and 517 nm of emission (for calcein) and at 528 nm of
excitation and 617 nm of emission (for ethidium homodimer-1) in a region of the slide randomly chosen. Images obtained with these two different excitation/
emission wavelength were collected merged using the software Confocal Assistant version 4.02 (Bio-Rad, Hercules, CA), and finally was quantified the number of
dead and live cells. In this figure is displayed a typical preparation showing live (green) and dead (red) cells. After 3 h of preincubation with or without inhibitor,
percentage of live cells was above 90% of total in both panels. These results are representative of eight others (see Table 2).
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those typically obtained after the procedure used to isolate rat
pancreatic acini [26,40,54,55]. These results indicate that 20
AM rottlerin does not alter the viability of pancreatic acini, at
least within incubation periods up to 3 h. Furthermore, our
results show that the inhibitory effects induced by rottlerin in
pancreatic acini are not due to a decrease on the amount of
viable cells.
4. Discussion
PKCs are a family of phospholipid-dependent serine/
threonine protein kinases that are activated by a very largeTable 2
Effects of rottlerin on viability of pancreatic acinar cells
Cellular viability
No addition Rottlerin (20 AM–3 h)
Dead (%) Alive (%) Dead (%) Alive (%)
EXP01 12.50 87.50 10.66 89.34
EXP02 7.64 92.36 6.04 93.96
EXP03 4.24 95.76 6.27 93.73
EXP04 8.62 91.38 10.76 89.24
EXP05 3.16 96.84 8.44 91.56
EXP06 4.83 95.17 9.66 90.34
EXP07 6.92 93.08 5.00 95.00
EXP08 8.23 91.77 8.11 91.89
EXP09 6.21 93.79 7.12 92.88
MeanTS.E.M. 6.93T0.93 93.07T0.93 8.01T0.69 91.99T0.69
Pancreatic acinar cells were incubated for 3 h without or with 20 AM rottlerin
and then cellular viability was assess using the Molecular Probes LIVE/DEAD
Viability/Cytotoxicity Kit for animal cells, as described in Methods and in Fig.
7 legend. Results from nine independent viability experiments are shown. Data
are expressed as percent of dead and live cells in the acinar population without
pretreatment (two left columns) or pretreated with 20 AM rottlerin (two right
columns).number of extracellular signals and in turn modify the activities
of a wide variety of cellular proteins including receptors,
enzymes, cytoskeletal proteins and transcription factors [2–5].
Thus, PKC has a central point in cellular signaling processes. To
date the extended PKC family includes 11 structurally related
isoenzymes. The cPKC are primarily activated by calcium,
phospholipids, diacylglycerol, or phorbol esters. The nPKC and
aPKC lack the calcium binding domain and are, therefore,
calcium insensitive. The aPKC lack one of the cysteine-rich
sequences that is the site of interaction with phospholipids and
diacylglycerol/phorbol esters and, thus, they are not affected by
diacylglycerol or phorbol esters [3,4,6].
PKC-y is the most widely studied member of the nPKC
subfamily. PKC-y has been found widely distributed in most
tissues and cell types examined [2,3]. By using different
approaches it has been described that PKC-y in various cells is
important in growth inhibition [56,57], differentiation [58],
apoptosis [59–63], tumor suppression [64], motility [65–67]
and secretion [68,69] (reviewed in [2] and [10]). In pancreatic
acinar cells PKC-y has been show to be important for
phosphorylation and activation of the focal adhesion tyrosine
kinase PYK2/CAKh by TNF-a [36] or CCK [37]. Moreover,
PKC-y has been involved in these cells in NF-nB activation by
long-term incubation with CCK or treatment with TNF-a
[37,38]. Because NF-nB activation is an early event in the
course of pancreatitis, it has been proposed that PKC-y may
play an important role in this process [37,38]. Recently has
been also proposed that this isoform is involved in stimulation
of the secretion in pancreatic acini [11].
In order to investigate the role of PKC’s signal transduction
pathways various pharmaceutical agents are frequently used
which are reported to function as selective activators or
inhibitors of various PKC isoforms [8,70]. Compounds that
selectively activate PKC-y [71] have been developed, but are
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inhibitory action against PKC-y or other isoforms [8,70].
Rottlerin (mallotoxin) that was described in 1994 as a specific
PKC-y inhibitor [9], is a polyphenol purified from the common
Indian tree Ro¨ttlera tinctoria (Mallotus philippinensis. Mu¨ell.
Arg.) [9]. Rottlerin was initially reported to inhibit PKC-y
(IC50=3–6 AM) more potently than other PKC isoforms and
other unrelated kinases [9]. Specifically, rottlerin was reported
to inhibit PKC-y 5- to 10-fold more potently than PKC-a or
PKC-h, and 13- to 33-fold more potently than PKC-q, PKC-~
or PKC-D [9]. This compound also weakly inhibited PKA
(IC50=78 AM) and casein kinase II (IC50=30 AM), but was
inactive against Src kinases (IC50>100 AM) [9]. Additionally,
rottlerin was reported to inhibit in the low micromolar range
calmodulin-dependent kinase III (IC50=5.3 AM) [72]. Thus,
rottlerin inhibited calmodulin-dependent kinase III with similar
potency to inhibiting PKC-y, but this potency for the two
kinases was 5- to 10-fold greater than the effect seen in other
kinases, including additional PKC isoforms [9,72]. Subse-
quently rottlerin has been extensively used as specific PKC-y
inhibitor [2,10–16].
In the last few years a number of studies have reported that
rottlerin had other effects in cells than just inhibition of PKC-y
[17,73–75]. In one study [17] rottlerin (20 AM) was reported to
inhibit the activity of additional unrelated kinases, such as p38-
regulated/activated kinase (IC50=1.9 AM), MAPK-activated
protein kinase 2 (IC50=5.4 AM), protein kinase A (inhibition
by 83%) and glycogen synthase kinase 3-beta (inhibition by
87%). Moreover, recent studies have shown that rottlerin was
not effective in blocking PKC-y activity in vitro [17,18]. It was
also reported that rottlerin, genistein and tyrphostin A25 caused
inhibition of the ATP-dependent binding of DNA to N-OH-IQ,
a carcinogenic heterocyclic amine, being this effect not related
to the target kinase because the inhibition described did not
occur at the enzyme level [76]. In subsequent studies, rottlerin
was reported to cause a general inhibition of the mitochondrial
metabolism [18–20] which correlated with a depletion of the
cellular ATP concentration and with a general inhibition of
cellular processes [19,20]. In contrast, a previous report in two
human pancreatic carcinoma cell lines showed that rottlerin did
not alter the cellular ATP concentration [16]. These apparently
contradictory results could rely on the differences in the energy
metabolism between normal and cancer cells lines. While most
cancer cells synthesize ATP mainly through glycolysis,
therefore, rottlerin-induced mitochondria uncoupling may not
significant affects their ATP levels, energy production in non-
transformed cells depends critically on mitochondria metabo-
lism [77,78]. This possibility was also suggested in a previous
study, where preincubation with rottlerin did not inhibit PKC-y
TyrP in PC12 cells, although it caused a full inhibition of PKC-
y TyrP in freshly isolated parotid acini, proposing that the
differential effect of rottlerin on PKC-y TyrP was due to
differences in the energy metabolism between cultured cells
and freshly isolated acini [19].
In the present study, we have found that rottlerin fully
inhibited the CCK-stimulated kinase activity, TyrP and
translocation to membrane of PKC-y. In other studiesperformed in different cells rottlerin also displayed a similar
effect on the PKC-y TyrP [69,74], kinase activity [60,66,79]
and translocation to the membrane [80,81], nucleus [62] or
mitochondria [81] triggered by various stimuli. Because of its
ability to inhibit PKC-y activation-related processes in rat
pancreatic acini, our results at this point suggest that rottlerin
could be a useful tool in assessing the role of PKC-y could play
in these cells. However, rottlerin caused a marked time-
dependent depletion of the cellular ATP content which is in
agreement with previous reports in parotid acinar cells [19] and
3T3-L1 adipocytes [20], where it is described as a rapid and
full depletion of cellular ATP content by rottlerin. As all the
processes studied here are highly dependent on energy
metabolism, the decrease of cellular ATP concentration could
be the cause underlying rottlerin inhibitory effects in pancreatic
acini. This conclusion is supported by the fact that the
inhibitory effect of rottlerin on pancreatic secretion, protein
tyrosine phosphorylation, MAPK activation and PKC isoforms
activation, was mimicked by a classical mitochondrial uncou-
pler, FCCP. We also found that the mitochondria uncoupler
effectively inhibits PKC-y translocation and TyrP similarly to
rottlerin. Because PKC-y in pancreatic acini is activated after
its translocation and TyrP [35], these results, together with
studies showing a lack of effect of rottlerin on PKC-y activity
in vitro [17,19], suggest that the rottlerin-mediated inhibition of
PKC-y activity in intact cells is likely due to the depletion of
cellular ATP and probably not due to its direct and selective
action on PKC-y. However, a recent study has shown that
different PKC inhibitors, including rottlerin, induced a consis-
tent flavoprotein oxidation in cardiac myocytes and proposed
that PKC may act as a regulator of the mitoKATP channel to
prevent excessive mitochondrial oxidation [82]. Besides that
this proposed effect of rottlerin on mitochondria metabolism
could be explained through a specific PKC-y inhibition [82],
our results clearly showed that rottlerin and FCCP are able to
inhibit the activity of several PKC isoforms in pancreatic acini,
indicating that rottlerin not only selectively inhibited PKC-y.
Therefore, rottlerin should not be a useful tool in the search of
specific roles of different PKC isoforms present in a particular
type of cell.
Rottlerin did not alter the viability of pancreatic acinar cells
which is in agreement with other studies in other cells using a
similar incubation time. In fact, rottlerin likely increased
pancreatic h cell viability, where it protected these cells from
fatty acid-mediated toxicity [63,83]. Moreover, a protective
action of rottlerin against apoptosis has been described in a
number of cells [60–63]. In contrast, in the human pancreatic
carcinoma MIA PaCa-2 and PANC-1 cell lines it is reported
that a longer preincubation time with rottlerin (24 and 48 h)
increases apoptosis in these cells [16]. These results indicate
that rottlerin has different effects on cell survival depending of
the cell type and the incubation time. Our results suggest that
the inhibitory effects induced by rottlerin are not explained by a
decrease in the viability of pancreatic acini.
Findings in this work show that short- and long-term effects
of rottlerin could be mainly attributed to its inhibitory effect on
energy metabolism rather than a specific PKC-y inhibition,
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20]. Rottlerin-mediated effects on apoptosis or cell viability
discussed above may be also explained by its effects on cellular
ATP content. It has been proposed that a partial maintenance of
ATP levels is necessary for the downstream events of
apoptosis, although a substantial drop in ATP levels occurs
late in the process [85]. Thus, cellular ATP depletion by
rottlerin in a number of different cells likely improves short-
term cellular viability and reduce proapoptotic mechanisms,
probably by inactivation of several ATP-dependent processes
that trigger apoptosis and death [63] that may also include
PKC-y-dependent mechanisms [61]. Supporting this possibil-
ity, it has been described a protective effect of FCCP from
apoptosis induced by serine/threonine kinase inhibitors in
leukaemia HL60 and CCRF-CEM cell lines [84].
In summary, several findings in this work support the
conclusion that rottlerin’s widespread effects in pancreatic
acini are likely due to its effect on cellular ATP depletion,
which makes it useless as a chemical tool to assess the PKC-y
role in these cells. First, rottlerin as well as two classical
mitochondrial uncouplers, FCCP and CCCP markedly re-
duced ATP content in pancreatic acini. Second, PKC-
dependent and -independent stimulation of amylase secretion
in rat pancreatic acini was inhibited by rottlerin as well as by
a mitochondrial uncoupler. Third, a full inhibition in CCK-
stimulated general TyP, p125FAK TyrP and MAPK activation,
pathways that involve partially PKC-independent mechan-
isms, was obtained by rottlerin as well as by a mitochondrial
uncoupler. It is important to mention that the time-course
inhibition of these mentioned pathways obtained by each one
of inhibitors, rottlerin and FCCP, totally correlated with their
respective time-courses of depletion of cellular ATP content.
Fourth, although rottlerin effectively inhibits PKC-y tyrosine
phosphorylation and translocation, these effects are complete-
ly mimicked by the mitochondrial uncoupler FCCP, showing
that ATP depletion could also be responsible for the rottlerin
inhibition of PKC-y activation-related processes. Fifth, rot-
tlerin inhibited phosphorylation residues that lead to the
activation of PKC-y and also other PKC isoforms present in
pancreatic acini with a similar potency, including the
activation of protein kinase D (PKD/PKC-A). Again, the
effect of rottlerin on the activation of several PKC isoforms is
indistinguishable from that obtained with a mitochondrial
uncoupler. All together, our results and those obtained in
different cells [18–20,73,74], as well as in cellular free
systems [17,19,76], suggest that if rottlerin is used to study
the role of PKC-y in cellular processes it is essential to keep
in mind that it may uncouples mitochondrial respiration and
deplete cellular ATP levels and inhibit other PKC isoforms.
Our results give reasons for a more careful choice of rottlerin
as a tool for PKC-y investigation.
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